Harrow Secures J-Code for IOPIDINE, but Financial and Regulatory Risks Undermine Bull Case

What happened

Harrow announced that IOPIDINE 1% has been assigned a permanent J-Code (J2374) by CMS, which should streamline Medicare reimbursement for this ophthalmic solution. This move aligns with the company's strategy to enhance access for its branded portfolio, similar to prior J-Code wins for products like IHEEZO. However, the DeepValue report highlights that Harrow operates with elevated leverage, including net debt/EBITDA of 8.21x and interest coverage below 1x, despite recent revenue growth from flagships like IHEEZO and VEVYE. The company's financial health is strained by volatile free cash flow, persistent net losses, and regulatory risks from its New Jersey outsourcing facility, which could face enforcement actions. While the J-Code for IOPIDINE is a positive development, it represents a minor product in Harrow's portfolio and does not materially address the broader execution and balance sheet challenges.

Implication

The permanent J-Code for IOPIDINE could improve Medicare reimbursement and support incremental revenue growth for this product. However, IOPIDINE is not a core growth driver; Harrow's success hinges on IHEEZO and VEVYE, which face reimbursement and competitive pressures in a crowded market. Investors must recognize that Harrow's balance sheet remains stretched, with substantial interest expenses from its 8.625% 2030 notes, constraining financial flexibility and increasing vulnerability to earnings shortfalls. Regulatory scrutiny, particularly around the New Jersey outsourcing facility, continues to pose risks of operational disruptions or consent decrees that could impair cash generation. Overall, this news is a small positive but does not alter the need for sustained free cash flow and deleveraging to shift the investment thesis away from a SELL bias.

Thesis delta

The J-Code issuance for IOPIDINE is an incremental positive that aids reimbursement efforts, but it does not shift the fundamental thesis. Harrow's valuation remains rich relative to its financial risks, with high leverage, volatile cash flow, and regulatory exposure unchanged, keeping the POTENTIAL SELL recommendation intact.